Telesta Therapeutics : Annual General Meeting, 2015

License revenue

130

-

-

-

Pre-commercial production (COS)

1,471

-

-

-

Research and development

1,405

1,087

6,757

6,909

Administration

1,540

1,236

5,259

5,442

Financial expenses

230

180

2,353

5,038

Foreign Exchange

(723)

8

10

373

Termination benefits

66

110

1,629

Gain on sale of of PPE

(11)

(11)

(252)

(Recovery) expense shareholder action

(50)

(50)

355

Discontinued operations - AH

317

(48,080)

Discontinued operations - Econiche

137

415

1,042

22,721

Comprehensive income

(3,930)

(2,931)

(15,787)

5,865

Assets:

Cash

34,277

4,112

Liabilities and Equity:

Current liabilities - Accounts payable

2,974

2,805

Marketable securities

5,872

-

Severance

547

738

Accounts receivable - trade/escrow

2,690

2,407

Provisions

-

74

Prepaids

121

197

Current portion employee benefit

398

398

Current portion debt & Govt assistance

2,165

1,025

Current assets

42,960

6,716

Current liabilities

6,084

5,040

PP&E

1,722

1,772

Long term debt

13

9

Intangible

1,829

1,979

Employee benefit

1,083

1,176

LT Escrow

1,200

1,200

Government assistance ITO

1,769

1,721

Assets held for sale

10,315

10,229

Conditionally repyable on future sales

8,788

9,731

Liabilities of assets held for sale

8,759

9,945

Total assets

58,026

21,896

Total Liabilities

26,496

27,622

Common Shares

181,753

139,501

Paid up capital

12,882

13,948

Accumulated Comprensive Income

(9)

(9)

Deficit/Equity

(163,096)

(159,166)

Shareholders Equity

31,530

(5,726)

Total liabilities and shareholders equity

58,026

21,896